title: Effects of simvastatin on pro-inflammatory cytokines in patients with hypercholesterolemia.
abstract: BACKGROUND
  The role of inflammation in the development of atherosclerosis and its complications has been recently documented. Pro-inflammatory cytokines are among many postulated factors. It is possible that the imbalance between protective cytokines and cytokines affecting endothelial function is one of the underlying mechanisms of myocardial ischaemia.
  
  
  OBJECTIVE
  To examine the effects of simvastatin on IL-2 and TNFalpha levels in patients with hypercholesterolemia.
  
  
  METHODS
  The study group consisted of 64 males (age 20-65 years) with hypercholesterolemia. The control group was composed of 10 healthy male volunteers (age 25-40 years) with normal lipid profile. Total cholesterol, LDL-cholesterol, IL-2 and TNFalpha were measured in both groups at baseline, after three months of dietary treatment, and after a further three months of simvastatin therapy.
  
  
  RESULTS
  Simvastatin caused a significant decrease in the total and LDL-cholesterol levels compared both with baseline measurements (p=0.0001) and after dietary treatment (p=0.0001). Moreover, simvastatin significantly reduced the IL-2 plasma concentration (p=0.0003). There were no significant differences between IL-2 levels before and following dietary treatment. The TNFalpha serum concentration significantly decreased following the implementation of diet (p=0.0001). Subsequent simvastatin therapy caused further decrease in the TNFalpha serum concentration but this difference did not achieve statistical significance.
  
  
  CONCLUSIONS
  A hypolipemic diet significantly decreases TNFalpha serum concentration without affecting the IL-2 level. The subsequent simvastatin therapy significantly reduces IL-2 but not TNFalpha when compared with the post-diet values.
authors.affiliation: Department of Internal Diseases, Silesian Medical Academy, Bytom, Poland.
authors.forename: Barbara
authors.initials: B
authors.lastname: Zubelewicz-Szkodzińska
authors.forename: Janusz
authors.initials: J
authors.lastname: Szkodziński
authors.forename: Aleksander
authors.initials: A
authors.lastname: Danikiewicz
authors.forename: Wojciech
authors.initials: W
authors.lastname: Romanowski
authors.forename: Adam
authors.initials: A
authors.lastname: Błazelonis
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Muc-Wierzgon
authors.forename: Anna
authors.initials: A
authors.lastname: Pietka-Rzycka
authors.forename: Zuzanna
authors.initials: Z
authors.lastname: Muryn
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D006937:Hypercholesterolemia / Q000178:diet therapy / Q000188:drug therapy*; D007376:Interleukin-2 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol; D019821:Simvastatin